By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Nxt2b has signed an agreement to purchase 49 percent of all outstanding shares of Swedish protein and molecular technologies firm Olink Bioscience for an undisclosed amount.
Westburg already is a distributor for Analytik Jena products.
Biovest is an investment firm led by Innogenetics Co-founder and Chairman Rudi Mariën.
The firms announced a deal to identify strategic investments in technology areas within agriculture "to support and complement Monsanto's interests and potential growth areas."
The UK firm will use the investment to further build partnerships with pharmaceutical and biotech firms and identify novel biomarkers.
Consort's Bespak division also will design disposable test cards that will be part of Atlas' rapid, point-of-care molecular diagnostics system.
The companies also converted roughly $8 million in Calando debt it owed Arrowhead into equity.
CytRx said it sold the shares for $7 million.
In addition to a challenging IPO market, experts said that private equity funding remains a challenge.
The alliance includes a $12 million equity investment from Bayer CropScience in Evogene.
Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.
The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.
Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.
In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.